Scarica l'app Stockscreener
0.776
8.71%
-0.074
Pre-mercato:
.79
0.014
+1.80%
Fractyl Health Inc Borsa (GUTS) Ultime notizie
GUTS SEC FilingsFractyl Health 10-K, 10-Q, 8-K Forms - Stock Titan
Fractyl Health director Ajay Royan buys $19,596 in company stock - Investing.com UK
Fractyl Health (NASDAQ: GUTS) director adds 23,000 shares in open-market buy - Stock Titan
Fractyl Health, Inc. 8-K Filing June 2026: Company Information, Nasdaq Listing, and Executive Details - Minichart
Fractyl Health Inc (GUTS) Cleared for RJVA-001 Trial. Let’s Look At Funding - Insider Monkey
Fractyl Health director William Bradley buys $50,328 in stock - Investing.com
Fractyl Health (NASDAQ: GUTS) 2026 meeting backs board and auditor - Stock Titan
Fractyl Health (GUTS) director buys stock and receives 22,500 options - Stock Titan
Fractyl Health (GUTS) awards 22,500 stock options to board director - Stock Titan
Fractyl Health (GUTS) awards director 22,500 options at $0.7318 - Stock Titan
Fractyl Health (GUTS) director Marc Elia receives 22,500-share stock option grant - Stock Titan
Fractyl Health (GUTS) director receives 22,500-stock-option board compensation grant - Stock Titan
Director Clive Meanwell gets 22,500 options at Fractyl Health (GUTS) - Stock Titan
Fractyl Health (NASDAQ: GUTS) director buys shares and receives options - Stock Titan
Fractyl Health (GUTS) CEO buys 25,000 open-market shares - Stock Titan
Fractyl Health CFO Smith Weber Lara purchases $13,708 in stock By Investing.com - Investing.com South Africa
Fractyl Health CFO Smith Weber Lara purchases $13,708 in stock - Investing.com
[Form 4] FRACTYL HEALTH, INC. Insider Trading Activity - Stock Titan
Fractyl Health reports one-year data on weight maintenance therapy - Investing.com UK
GUTS Reiterates by HC Wainwright & Co. -- Price Target Maintained at $8.00 - GuruFocus
Fractyl Health Reports Positive One-Year Results from REVEAL-1 Open-Label Study of Revita Procedure for Post-GLP-1 Weight Maintenance - marketscreener.com
Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure - markets.businessinsider.com
Fractyl Health Highlights One-Year Revita Obesity Results - TipRanks
Fractyl Health reports one-year data on weight maintenance therapy By Investing.com - Investing.com South Africa
Fractyl Health Reports Positive One-Year Results from REVEAL-1 Cohort, Highlighting Revita's Efficacy in Sustaining Weight Loss Post-GLP-1 Therapy - Quiver Quantitative
Revita study shows durable post-GLP-1 weight loss at Fractyl Health (GUTS) - Stock Titan
Fractyl Health Reports Positive One-Year REVEAL-1 - GlobeNewswire
Fractyl Health names Mike Zumdahl as market access head By Investing.com - Investing.com South Africa
Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy - The Manila Times
Fractyl Health names Mike Zumdahl as market access head - Investing.com
Nearly 1M leave GLP-1 therapy monthly; Fractyl hires market-access lead - Stock Titan
Fractyl Health, Inc. Announces Appointment of Mike Zumdahl to Senior Vice President, Market Access and Commercial Strategy - marketscreener.com
Fractyl Health Inc. (GUTS) Declines 2.7% as Stock Tests Critical Support Near $0.78Put Call Ratio - newsline.com
Fractyl Health (GUTS) Dips 3% as Stock Hovers Near Critical Support at $0.85Algorithmic Stock Picks - The Legal Advocate
GUTS Stock Chart | FRACTYL HEALTH INC (NASDAQ:GUTS) - ChartMill
Fractyl Health Q1 earnings call highlights - MSN
Fractyl Health Inc. (GUTS) Q1 2026 Earnings: Narrower Loss Surprises, Stock SlidesEarnings Cycle Report - thelegaladvocate.com
GUTS - Intellectia AI
Fractyl Health’s Pivotal Year: Inside the Earnings Call - TipRanks
Earnings call transcript: Fractyl Health Q1 2026 reports EPS beat, shares surge - Investing.com
Fractyl targets early Q4 2026 REMAIN-1 pivotal readout amid plans for late Q4 2026 de novo submission - MSN
Fractyl Health (GUTS) Is Up 14.0% After First GLP-1 Gene Therapy Trial Win And Profit Turnaround - Yahoo Finance
First human GLP-1 gene therapy trial gets green light - NewsNation
Nantahala’s 16.1M-share stake disclosed in Fractyl Health (NASDAQ: GUTS) - Stock Titan
[SCHEDULE 13G/A] FRACTYL HEALTH, INC. Amended Passive Investment Disclosure - Stock Titan
BofA Securities Maintains Fractyl Health(GUTS.US) With Buy Rating, Announces Target Price $2 - Moomoo
Fractyl Health (GUTS) stock jumps 21% after hours: Here's what you should know - MSN
TradingKey - TradingKey
A Look At Fractyl Health (GUTS) Valuation After New Gene Therapy Trial Approval And First Quarter Net Income - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS), UnitedHealth (UNH) and TELA Bio (TELA) - The Globe and Mail
SilverArc and Devesh Gandhi report 3.6M shares in Fractyl Health (GUTS) - Stock Titan
Fractyl Health | 10-Q: Q1 2026 Earnings Report - Moomoo
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Morgan Stanley Maintains Fractyl Health(GUTS.US) With Hold Rating, Maintains Target Price $2 - Moomoo
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):